Skip to main content
    N

    Neuphoria Therapeutics Inc (NEUP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.48
    -0.07 (-2.75%)

    Market Cap: $13.80M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Neuphoria Therapeutics Inc (NEUP) Financials: Revenue, Profit and Cash Flow

    Updated Sep 2, 2026. Financial statements from company filings, amounts in US dollars.

    Neuphoria Therapeutics reported revenue of $1.17M for the fiscal year ended Jun 30, 2026, down 92.5% from the year before. That year, net income was -$13.45M with a net margin of -1145.7% and operating cash flow was -$12.35M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$505.06K.

    Revenue and Margins

    Over the 9 years to Jun 2026, revenue fell from $4.13M, a compound annual decline of 13.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$1.17M-92.5%100.0%-1401.1%-1145.7%
    Jun 2025$15.65MN/A100.0%-7.2%-2.4%
    Jun 2024$0N/AN/AN/AN/A
    Jun 2023$0-100.0%N/AN/AN/A
    Jun 2022$188.85K+4266.6%100.0%-9917.0%-7955.8%
    Jun 2021$4.33K-86.6%-53024.6%-251187.4%-151078.1%
    Jun 2020$32.27K-98.8%-6935.5%-29821.1%-15254.9%
    Jun 2019$2.68M-2.9%100.0%-401.6%-252.8%
    Jun 2018$2.76M-33.3%100.0%-771.8%-668.3%
    Jun 2017$4.13MN/A100.0%-261.5%-125.6%
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Mar 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Revenue$1.17M$15.65M$0$0$188.85K$4.33K$32.27K$2.68M$2.76M$4.13M
    Cost of revenue$0$0$0$0$0$2.30M$2.27M$12.13M$25.25M$24.22M
    Gross profit$1.17M$15.65M$0$0$188.85K-$2.29M-$2.24M$2.68M$2.76M$4.13M
    Research and development$3.55M$9.01M$9.42M$13.07M$11.05M$4.33M$4.03M$6.29M$18.55M$18.61M
    Operating income-$16.45M-$1.13M-$17.89M-$21.98M-$18.73M-$10.86M-$9.62M-$10.76M-$21.28M-$10.80M
    Net income-$13.45M-$369.63K-$15.49M-$21.38M-$15.02M-$6.53M-$4.92M-$6.77M-$18.43M-$5.19M
    EBITDA-$13.59M-$341.61K-$15.14M-$21.32M-$15.13M-$6.67M-$4.17MN/AN/A-$3.75M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Mar 2023
    Revenue$0$0$0-$13.27K$15.00M$662.72K$0$0$0$0$0-$44.72K
    Gross profit$0-$165.79K$0-$13.27K$15.00M$662.72K$0-$165.69K$0$0$0$3.58M
    Operating income-$1.21M-$6.08M-$5.65M-$5.84M$11.98M-$3.70M-$5.65M-$5.48M-$2.39M-$4.55M-$5.47M-$11.04M
    Net income-$505.06K$2.79M-$9.91M-$8.88M$11.26M-$1.94M-$9.91M-$2.69M-$2.78M-$4.55M-$5.47M-$5.28M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents of $19.87M were 69.2% of total assets of $28.71M, against total liabilities of $4.11M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$28.71M$28.59M$27.65M$28.56M$45.10M$40.77M$23.68M$37.58M$47.80M$64.61M
    Current assets$21.07M$15.04M$13.19M$13.33M$28.87M$23.24M$5.73M$17.60M$26.39M$41.86M
    Cash and equivalents$19.87M$14.21M$12.61M$12.10M$23.18M$21.41M$3.15M$9.79M$18.31M$32.95M
    Total liabilities$4.11M$9.59M$10.16M$6.55M$5.80M$5.01M$14.97M$25.18M$35.34M$33.52M
    Short-term debtN/A$226.49K$155.11K$211.83K$0$0$4.09M$5.92M$4.29M$6.53M
    Shareholder equity$24.60M$19.00M$17.49M$22.01M$39.30M$35.76M$8.71M$12.39M$12.46M$31.09M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$28.71M$34.81M$36.60M$27.34M$43.44M$30.71M$36.60M$27.34M$27.65MN/A$38.86M$22.92M
    Total liabilities$4.11M$5.39M$6.90M$14.83M$14.57M$4.72M$6.90M$14.83M$10.16M-$30.35M$9.82M$5.85M
    Cash and equivalents$19.87M$19.44M$22.17M$13.65M$21.59M$17.04M$22.17M$13.65M$12.61MN/A$14.87M$8.08M
    Shareholder equity$24.60M$29.42M$29.70M$12.51M$28.87M$26.00M$29.70M$12.51M$17.49M$30.35M$29.04M$17.07M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow-$12.35M$77.23K-$14.68M-$14.64M-$15.21M-$5.66M-$2.70M-$10.91M-$15.02M-$1.44M
    Capital expendituresN/A$0$0N/A$1.54K$1.10K$5.33K$69.28K$358.11K$247.51K
    Free cash flowN/A$77.23K-$14.68MN/A-$15.21M-$5.66M-$2.70M-$10.98M-$15.38M-$1.69M
    Share repurchasesN/AN/AN/AN/AN/A$312.15K$33.35KN/AN/AN/A
    Investing cash flow$0$0$0$0$487.92K-$60.26K-$134.93K$138.42K$59.68K$953.94K
    Financing cash flow$17.92M$1.53M$15.11M$3.86M$22.71M$23.71M-$3.70M$3.05M$1.94M-$2.08M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow$1.21M-$3.87M-$6.44M-$3.79M-$3.59M$13.89M-$3.79M-$3.01M-$3.30M-$3.95M-$4.43MN/A
    Capital expendituresN/A$2$0$2$3$0$3$0$0$0$0$0
    Free cash flowN/A-$3.87M-$6.44M-$3.79M-$3.59M$13.89M-$3.79M-$3.01M-$3.30M-$3.95M-$4.43MN/A
    Last 12 quarters

    Frequently Asked Questions About NEUP

    What is Neuphoria Therapeutics' annual revenue?

    Neuphoria Therapeutics reported revenue of $1.17M for the fiscal year ended Jun 30, 2026.

    How fast is Neuphoria Therapeutics' revenue growing?

    Revenue was down 92.5% for the fiscal year ended Jun 30, 2026 compared with the year before.

    Is Neuphoria Therapeutics profitable?

    No. Neuphoria Therapeutics reported net income of -$13.45M for the fiscal year ended Jun 30, 2026, with a net margin of -1145.7%.

    How much debt does Neuphoria Therapeutics have?

    The balance sheet dated Jun 30, 2026 reported cash and equivalents of $19.87M.

    What is NEUP's profit margin?

    For the fiscal year ended Jun 30, 2026, Neuphoria Therapeutics reported gross margin of 100.0%, operating margin of -1401.1% and net margin of -1145.7%.